Search Within

Paul Marks

Formats
  1. Journal Article (121)
  2. Meeting Abstract (47)
  3. Book Section (10)
  4. Book Whole (4)
  5. Conference Paper (4)
Groups
  1. Department of Medicine (18)
  2. Center for Hematologic Malignancies (15)
  3. Solid Tumor Oncology Division (14)
  4. Surgery (13)
  5. GSK Faculty (12)
  6. Genitourinary Oncology Service (12)

More Groups

People
  1. Richard Rifkind (113)
  2. Victoria Richon (77)
  3. Lang Ngo (27)
  4. Gisela Venta-Perez (20)
  5. William Kelly (16)
  6. Weisheng Xu (13)

More People

Years
  1. 2015 (2)
  2. 2014 (2)
  3. 2013 (3)
  4. 2012 (4)
  5. 2011 (3)
  6. 2010 (6)

More Years

Publications
  1. Proceedings of the National Academy of Sciences of the United States of America (35)
  2. Proceedings of the American Association for Cancer Research Annual Meeting (19)
  3. Cancer Research (15)
  4. Blood (9)
  5. Clinical Cancer Research (9)
  6. Anticancer Research (5)

More Publications

Publishers
  1. American Association for Cancer Research (48)
  2. National Academy of Sciences (35)
  3. American Society of Hematology (9)
  4. Nature Publishing Group (8)
  5. Elsevier Inc. (7)
  6. John Wiley & Sons (6)

More Publishers

Results (186)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces thioredoxin-binding protein-2 which blocks thioredoxin function
    Meeting Abstract

    Butler, L. M.; Zhou, X.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors and the treatment of cancers
    Meeting Abstract

    Rifkind, R. A.; Richon, V.; Breslow, R.; Marks, P. A.
    Abstracts of Papers of the American Chemical Society (2002)

    Fulltext@MSK | Save
  • A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W.; O'connor, O.; Richon, V. M.; Tong, W.; Rao, T. D.; Chiao, J.; O'Brien, J. P.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Richon, V.; Moskowitz, C. H.; Zelenetz, A. D.; Macgregor-Cortelli, B.; Curly, T.; Richardson, S.; Tong, W.; Rifkind, R.; Marks, P.; more...
    Blood (2002)

    Fulltext@MSK | Save
  • Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors
    Journal Article

    Cohen, L. A.; Marks, P. A.; Rifkind, R. A.; Amin, S.; Desai, D.; Pittman, B.; Richon, V. M.
    Anticancer Research (2002)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors: From target to clinical trials
    Journal Article

    Kelly, W. K.; O'Connor, O. A.; Marks, P. A.
    Expert Opinion on Investigational Drugs (2002)

    Fulltext@MSK | Save
  • The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
    Journal Article

    Butler, L. M.; Zhou, X.; Xu, W. S.; Scher, H. I.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.
    Proceedings of the National Academy of Sciences of the United States of America (2002)

    Fulltext@MSK | Save
  • The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces differentiation of human breast cancer cells
    Meeting Abstract

    Munster, P. N.; Rosen, N.; Rifkind, R.; Marks, P.; Richon, V.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Clinical development of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Kelly, W.; Wang, E. S.; Richon, V.; Moskowitz, C.; Tong, W.; Donnelly, G.; Zelenetz, A. D.; Moore, M. A. S.; Rifkind, R. A.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • Inhibitors of histone deacetylase are potentially effective anticancer agents
    Journal Article

    Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save